Literature DB >> 1537128

Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty.

G S Roubin1, A D Cannon, S K Agrawal, P J Macander, L S Dean, W A Baxley, J Breland.   

Abstract

BACKGROUND. Acute closure remains a significant limitation of percutaneous transluminal coronary angioplasty (PTCA) and underlies the majority of ischemic complications. This study details the clinical and angiographic characteristics of a series of patients receiving an intracoronary stent device to manage acute and threatened closure and presents the early clinical results. METHODS AND RESULTS. From October 1989 through June 1991, 115 patients undergoing PTCA received intracoronary stents to treat acute or threatened closure in 119 vessels. Sixty-three percent had multivessel coronary disease, 33 (29%) had undergone prior coronary artery bypass grafting (CABG), and 52 (45%) had had previous PTCA. Using the American College of Cardiology/American Heart Association (ACC/AHA) classification, 15% of lesions were class A, 55% were class B, and 30% were class C. Eight patients were referred with severe coronary dissection and unstable angina after PTCA at other institutions. Acute closure was defined as occlusion of the vessel with TIMI (Thrombolysis in Myocardial Infarction) 0 or 1 flow immediately before stent placement. Threatened closure required two or more of the following criteria: 1) a residual stenosis greater than 50%, 2) TIMI grade 2 flow, 3) angiographic dissection comprising extraluminal dye extravasation and/or a length of greater than 15 mm, 4) evidence of clinical ischemia (either typical angina or ECG changes). Twelve vessels (10%) met the criteria for acute closure, and 87 vessels (73%) satisfied the criteria for threatened closure. Twenty vessels (17%) failed to meet two criteria. Stenting produced optimal angiographic results in 111 vessels (93%), with mean diameter stenosis (+/- 1 SD) reduced from 83 +/- 12% before to 18 +/- 29% after stenting. Overall, in-hospital mortality was 1.7% and CABG was required in 4.2%; Q wave myocardial infarction (MI) occurred in 7% and non-Q wave MI in 9%. Stent thrombosis occurred in nine patients (7.6%). For the 108 patients who presented to the catheterization laboratory without evolving MI, Q wave MI occurred in 4% and non-Q wave MI occurred in 7%. Angiographic follow-up has been performed in 81 eligible patients (76%), and 34 patients (41%) had a lesion of greater than or equal to 50%. CONCLUSIONS. This stent may be a useful adjunct to balloon dilatation in acute or threatened closure. Randomized studies comparing this stent with alternative technologies are required.

Entities:  

Mesh:

Year:  1992        PMID: 1537128     DOI: 10.1161/01.cir.85.3.916

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  37 in total

1.  Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 2.  Stent thrombosis: historical perspectives and current trends.

Authors:  D E Cutlip
Journal:  J Thromb Thrombolysis       Date:  2000-08       Impact factor: 2.300

Review 3.  Role of stenting in coronary revascularisation.

Authors:  A H Gershlick
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

Review 4.  [Antiplatelet therapy after coronary stenting and its importance in total joint arthroplasty].

Authors:  N Harrasser; T Harnoss; F Brettner; F Liska; M Pauschinger
Journal:  Orthopade       Date:  2012-06       Impact factor: 1.087

5.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

6.  Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Per Olav Vandvik; A Michael Lincoff; Joel M Gore; David D Gutterman; Frank A Sonnenberg; Pablo Alonso-Coello; Elie A Akl; Maarten G Lansberg; Gordon H Guyatt; Frederick A Spencer
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

7.  Bioclickable and mussel adhesive peptide mimics for engineering vascular stent surfaces.

Authors:  Zhilu Yang; Xin Zhao; Rui Hao; Qiufen Tu; Xiaohua Tian; Yu Xiao; Kaiqing Xiong; Miao Wang; Yonghai Feng; Nan Huang; Guoqing Pan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

8.  Coating of cardiovascular stents with a semiconductor to improve their hemocompatibility.

Authors:  A Bolz; M Amon; C Ozbek; B Heublein; M Schaldach
Journal:  Tex Heart Inst J       Date:  1996

9.  Mechanical features and in vivo imaging of a polymer stent.

Authors:  W J van der Giessen; C J Slager; E J Gussenhoven; H M van Beusekom; R A Huijts; J C Schuurbiers; R A Wilson; P W Serruys; P D Verdouw
Journal:  Int J Card Imaging       Date:  1993-09

10.  Temporary stent as a bail-out device during percutaneous transluminal coronary angioplasty: preliminary clinical experience.

Authors:  J S Gibbs; U Sigwart; N P Buller
Journal:  Br Heart J       Date:  1994-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.